Skip to content

Study · Case report or series · n = 2 · 2014

2 results

[Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review].

Shao WM, Bai WJ, Chen YM, Liu L, Wang YJ

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences1 Aug 2014Cited by 2 (Europe PMC)

PMID25131486 (opens in a new tab)PepBankPUB-25131486
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In two patients with hypogonadotropic hypogonadism from pituitary stalk interruption syndrome, androgen deficiency syndrome improved after pulse infusion of gonadorelin via micropump.

    In plain wordsIn two patients with hypogonadotropic hypogonadism, symptoms of low androgens improved after gonadorelin pulses from a micropump.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    Not applicableAndrogen deficiency syndrome
    Study

    n = 2

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · pulse infusion via micropump · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    their syndrome of androgen deficiency improved
    1 context sentence
    Summary · context
    Two cases of hypogonadotropic hypogonadism caused by pituitary stalk interruption syndrome treated by pulse infusion of gonadorelin via micropump were reported, and their clinical features and the treatment process of pulse infusion of gonadorelin via micropump summarized.
  2. 02HumanCase report or seriesEfficacy outcome

    In two patients with hypogonadotropic hypogonadism from pituitary stalk interruption syndrome, gonadotropin levels rose by the end of 12 weeks of pulse gonadorelin infusion via micropump.

    In plain wordsIn two patients with hypogonadotropic hypogonadism, gonadotropin levels rose by the end of 12 weeks of gonadorelin pulses from a micropump.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseGonadotropin levels
    Study

    n = 2

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · pulse infusion via micropump · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    the gonadotropin levels promoted at the end of 12 weeks' follow-up
    1 context sentence
    Summary · context
    Two cases of hypogonadotropic hypogonadism caused by pituitary stalk interruption syndrome treated by pulse infusion of gonadorelin via micropump were reported, and their clinical features and the treatment process of pulse infusion of gonadorelin via micropump summarized.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02705014

Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome

Peking Union Medical College Hospitaln = 20Jan 2016 to est. Aug 2017

Hypogonadotropic Hypogonadism

Trial pageClinicalTrials.govUpdated 10 Mar 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.